Adverse effects are more common with<unk> s than with red blood cell<unk> s. 25 to 50 percent of people who receive<unk> s experience mild to moderate side effects, while 1 percent experience severe complications. Fever and chills are common side effects.<unk> s may affect the lungs, causing cough, difficulty breathing, low oxygen levels, and abnormal chest X-rays. These lung complications may potentially be fatal. A review paper found that the frequency of lung-related side effects ranged from 0 to 53 percent. Recipients can develop<unk> -transmitted diseases if pathogens are present in the donor blood, which is a particular problem with<unk> s because of their short shelf life, which means they must be transfused before infectious disease testing is complete. Infection with cytomegalovirus (CMV) is a concern, as this virus is found in white blood cells, so if the recipient is at risk of developing severe disease from CMV, it is recommended that<unk> s be collected from a CMV-negative donor. If the donor white blood cells are not irradiated, the recipient may be at risk of developing graft-versus-host disease. Finally, people who receive<unk> s may develop antibodies against the human leukocyte antigens found on the surface of white blood cells, which can predispose them to<unk>  reactions, decrease the lifespan of donor white blood cells in their circulation, and reduce the efficacy of platelet<unk> s and allogeneic stem cell transplants.
Granulocyte transfusion
Platelet transfusion
Exchange transfusion
Precipitate delivery
Transfusion therapy 
Packed red blood cells
Autologous blood therapy
Blood transfusion